articleThe LancetNov 21, 2012Closed access

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Mayo Clinic in Arizona · KU Leuven · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,882
total citations
FWCI
86.19
Percentile
100%
References
18
Citations per year

Authors

20

Topics & keywords

Keywords
  • Regorafenib
  • Medicine
  • Placebo
  • Clinical endpoint
  • Hazard ratio
  • Internal medicine
  • Interim analysis
  • Colorectal cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding